How long before digital Unicorns like Ola, Swiggy, Pharmeasy, and many others realize the humongous opportunity of delivering health care at the doorstep? Imagine an app like Ola, where instead of entering where you want to go, you enter the nature of your medical need/emergency and search and find a range of hospitals/doctors/paramedics who can act as the first responders and reach your home in an ambulance or a motorbike with an HCP as a pillion rider with all necessary equipment from the thermometer to defibrillator depending on the nature of the medical care needed and triage and route you/your loved ones to the nearest hospital with an indicative cost of treatment in partnership with health insurance companies?

Healthcare + Hospitality: India’s Next Big Export

Why Indian hospitals must go beyond treatment to build...

Generics Only

Special issue, focusing on the generic versus branded debate that has opened up post the government mandate that Doctors should online prescribe generics.

Not Digital Solutions alone, but Business Solutions that add Value to Customers delivered via Digital Platforms

Yesterday I received a WhatsApp from a famous shoe...

Contact Us
Terms of Service
Privacy Statement

Facebook

Twitter

Youtube

Healthcare Trends

IQVIA vs. PharmaTrac: Indian Pharma Market Data

Here is an analytical blog comparing the IQVIA MFR...

Indian Pharma Market in 2025: Decoding Growth, Therapy Shifts, and the Road Ahead

The latest PharmaTrac report for December 2025 offers a...

Orphan Drugs and Indian Pharma: Moving from Volume to Value?

Zydus’ ZYCUBO May Be the Proof Point the Industry...

Arjun Arunachalam: The Man Who Deleted Helium

For more than fifty years, the MRI industry treated...

Who Is Monitoring Quality in India’s Small Drug Units?

The Telangana Drugs Control Administration’s stop-use notice on a...

Marketing

IQVIA vs. PharmaTrac: Indian Pharma Market Data

Here is an analytical blog comparing the IQVIA MFR...

Indian Pharma Market in 2025: Decoding Growth, Therapy Shifts, and the Road Ahead

The latest PharmaTrac report for December 2025 offers a...

Orphan Drugs and Indian Pharma: Moving from Volume to Value?

Zydus’ ZYCUBO May Be the Proof Point the Industry...

Arjun Arunachalam: The Man Who Deleted Helium

For more than fifty years, the MRI industry treated...

Who Is Monitoring Quality in India’s Small Drug Units?

The Telangana Drugs Control Administration’s stop-use notice on a...

Policies/Sales

IQVIA vs. PharmaTrac: Indian Pharma Market Data

Here is an analytical blog comparing the IQVIA MFR...

Indian Pharma Market in 2025: Decoding Growth, Therapy Shifts, and the Road Ahead

The latest PharmaTrac report for December 2025 offers a...

Orphan Drugs and Indian Pharma: Moving from Volume to Value?

Zydus’ ZYCUBO May Be the Proof Point the Industry...

Arjun Arunachalam: The Man Who Deleted Helium

For more than fifty years, the MRI industry treated...

Who Is Monitoring Quality in India’s Small Drug Units?

The Telangana Drugs Control Administration’s stop-use notice on a...

Strategy

IQVIA vs. PharmaTrac: Indian Pharma Market Data

Here is an analytical blog comparing the IQVIA MFR...

Indian Pharma Market in 2025: Decoding Growth, Therapy Shifts, and the Road Ahead

The latest PharmaTrac report for December 2025 offers a...

Orphan Drugs and Indian Pharma: Moving from Volume to Value?

Zydus’ ZYCUBO May Be the Proof Point the Industry...

Arjun Arunachalam: The Man Who Deleted Helium

For more than fifty years, the MRI industry treated...

Who Is Monitoring Quality in India’s Small Drug Units?

The Telangana Drugs Control Administration’s stop-use notice on a...

Thought Leadership
Healthcare C-Suite Movements
Digital in Pharma
Events
- FFE+CEO RT
- BrandStorm
Solutions & Pricing
Partner

Hot topics

Careers in Medical Device Companies

Key Insights Thermo Fisher Scientific leads the industry with $42.88 billion...

Indian Pharma’s November 2025: How GLP-1s Rewired the Market

Indian pharma wrapped up November 2025 with serious velocity....

IMS Health Market Reflection Report for September 2016

The Indian Pharmaceutical Market (IPM) was valued at Rs. 10,278 crs in the month of September 2016 clocking a strong 10% growth over same period last year (SPLY). On a MAT September basis, the industry was valued at Rs. 111,022 crores and reflected a 13% growth with volumes contributing around 40% of this growth and New Introductions playing an important role with around 38% contribution to the overall growth.